Most Read Articles
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.

Early RAAS blockade improves renal outcomes in SLE patients with aPLN

06 May 2018

Short- and long-term renal outcomes improve with early renin–angiotensin–aldosterone system (RAAS) blockade with renin–angiotensin system inhibitors (RASI) in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study.

“The renal protective effect of RASI was independent of its antihypertensive and antiproteinuric effects,” the investigators said.

Demographic data, laboratory findings and renal histology by the time of kidney biopsy had no significant difference, but the RASI vs the non-RASI group had higher proteinuria levels (5.2; 2.8–8.8 vs 1.9; 0.6–2.8 g/day, respectively; p=0.005) and higher prevalence of hypertension (75 percent vs 29 percent, respectively; p=0.001).

There was no significant between-group difference in estimated glomerular filtration rate (eGFR), mean arterial pressure and proteinuria level at 12 months after kidney biopsy.

The RASI group had significantly higher improvement ratio of eGFR at 12 months compared with the non-RASI group (26 percent; –5 to 86 percent vs –2 percent; –20 to 20 percent, respectively; p=0.028). The rate of change in eGFR beyond 12 months was comparable between the two groups.

Kidney disease progression occurred in four (23 percent) patients in the non-RASI group and three (8 percent) patients in the RASI group during a mean follow-up of 80 months. Early RAAS blockade significantly reduced the risk of kidney disease progression (hazard ratio, 0.11; 0.02–0.59; p=0.010). Additionally, the two groups had similar proteinuria and hypertension controls.

In this study, the investigators analysed medical data of 57 SLE patients with biopsy-proven aPLN. Early RAAS blockade referred to the administration of RASI within 3 months following kidney biopsy and continued for ≥12 months.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.